title: Treatment of submacular haemorrhage in patients with neovascular age related macular degeneration.
abstract: To evaluate the efficacy of the pneumatic displacement of the submacular haemorrhage combined with the intravitreal injection of the tissue plasminogen activator. We present a retrospective clinical case series of nine eyes of nine patients that were treated with the intravitreal injection of the tissue plasminogen activator and expansile gas for the submacular haemorrhage due to the age related macular degeneration. We evaluated visual acuities and complications. Selected patients were additionally treated with the intravitreal bevacizumab injections after the procedure. Mean postoperative followup was 19 weeks. Four (4/9) eyes (44%) received additional treatment with the intravitreal bevacizumab during the postoperative period. Statistical analysis was performed using the Student's paired t-test. The mean visual acuity was 1.77 logMAR preoperatively and 1.06 logMAR postoperatively. After the surgery, 4 or more Snellen lines were gained in 7/9 eyes (78%). The improvement of the visual acuity postoperatively was statistically significant (p = 0.002). In 2/9 eyes (22%) the visual acuity did not get better after the procedure. We observed no complications during the follow up period. In our case series, pneumatic displacement of the submacular haemorrhage with the use of the intravitreal tissue plasminogen activator (with or without additional bevacizumab treatment in the selected cases) turned out to be an effective and safe method leading to the improvement of the visual acuity in the majority of cases. To maximise the treatment success, prompt referral to the retinal surgeon is imperative.
authors.affiliation: Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. xhlumi@hotmail.com
authors.forename: Xhevat
authors.initials: X
authors.lastname: Lumi
authors.forename: Marko
authors.initials: M
authors.lastname: Sulak
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D012166:Retinal Hemorrhage / Q000628:therapy*; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D010959:Tissue Plasminogen Activator